OBJECTIVE: To evaluate the role of interleukin 6 (IL-6) in the pathogenesis of bilateral erosive sacroiliitis in human tumour necrosis factor transgenic (hTNFtg) mice, an animal model of ankylosing spondylitis (AS). METHODS: Histological sections of the sacroiliac joints from hTNFtg and IL-6(-/-)hTNFtg mice were evaluated, and wild type and IL-6(-/-)mice served as controls. mRNA levels of inflammation and tissue degradation related genes isolated from sacroiliac joints were also evaluated by quantitative PCR. RESULTS: Severe, erosive bilateral sacroiliitis in 14-week-old hTNFtg animals was accompanied by an upregulation of mRNAs related to tissue inflammation such as matrix metalloproteinase 3 (MMP3), MMP9 and MMP13 or osteoclast activation such as cathepsin K and tartrate-resistant acid phosphatase. In addition, IL-6 was increased in the sera and in the sacroiliac joints of hTNFtg animals. However, high expression of these marker genes in sacroiliac joints from IL-6(-/-)hTNFtg mice was also found. Moreover, absence of IL-6 in these animals did not alter bilateral, erosive sacroiliitis when compared to hTNFtg littermates. CONCLUSIONS: IL-6 is not a crucial regulator in an animal model of TNF-mediated bilateral, erosive sacroiliitis. This finding questions the potential of IL-6 blockade as a new treatment in patients with AS.
OBJECTIVE: To evaluate the role of interleukin 6 (IL-6) in the pathogenesis of bilateral erosive sacroiliitis in humantumour necrosis factor transgenic (hTNFtg) mice, an animal model of ankylosing spondylitis (AS). METHODS: Histological sections of the sacroiliac joints from hTNFtg and IL-6(-/-)hTNFtg mice were evaluated, and wild type and IL-6(-/-)mice served as controls. mRNA levels of inflammation and tissue degradation related genes isolated from sacroiliac joints were also evaluated by quantitative PCR. RESULTS: Severe, erosive bilateral sacroiliitis in 14-week-old hTNFtg animals was accompanied by an upregulation of mRNAs related to tissue inflammation such as matrix metalloproteinase 3 (MMP3), MMP9 and MMP13 or osteoclast activation such as cathepsin K and tartrate-resistant acid phosphatase. In addition, IL-6 was increased in the sera and in the sacroiliac joints of hTNFtg animals. However, high expression of these marker genes in sacroiliac joints from IL-6(-/-)hTNFtg mice was also found. Moreover, absence of IL-6 in these animals did not alter bilateral, erosive sacroiliitis when compared to hTNFtg littermates. CONCLUSIONS:IL-6 is not a crucial regulator in an animal model of TNF-mediated bilateral, erosive sacroiliitis. This finding questions the potential of IL-6 blockade as a new treatment in patients with AS.
Authors: Fernando Kemta Lekpa; Cécile Poulain; Daniel Wendling; Martin Soubrier; Michel De Bandt; Jean Marie Berthelot; Philippe Gaudin; Eric Toussirot; Philippe Goupille; Thao Pham; Jérémie Sellam; Rémy Bruckert; Muriel Paul; Valérie Farrenq; Pascal Claudepierre Journal: Arthritis Res Ther Date: 2012-03-09 Impact factor: 5.156
Authors: Iain A Rankin; Thuy-Tien Nguyen; Diagarajen Carpanen; Jonathan C Clasper; Spyros D Masouros Journal: Ann Biomed Eng Date: 2019-05-30 Impact factor: 3.934
Authors: Silvia Hayer; Birgit Niederreiter; Marlene Kalkgruber; Konrad Wanic; Julia Maißner; Josef S Smolen; Daniel Aletaha; Stephan Blüml; Kurt Redlich Journal: Bone Joint Res Date: 2022-07 Impact factor: 4.410
Authors: Katelin R Haynes; Allison R Pettit; Ran Duan; Hsu-Wen Tseng; Tibor T Glant; Matthew A Brown; Gethin P Thomas Journal: Arthritis Res Ther Date: 2012-11-22 Impact factor: 5.156